Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
Registration successful
You now have access to the latest updates, events and resources.
Registration successful
You now have successfully registered for the event and for an account on this website.
In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number.
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Registration completed – pending validation
Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result of the validation process. Please note this could take up to 10 days.
In the meantime, you can continue to access all the unlocked content on this website.
Account activated - pending validation.
Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can continue to access the unlocked content of the website.
Registration completed - pending validation.
Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result of the validation process. Please note this could take up 10 days.
In the meantime, you can continue to access all the unlocked content on this website.
In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.
Keep asthma tamed through proactive control that lasts with Relvar.
Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
25% more patients see improvement vs other commonly used ICS/LABAs*2
Sustained efficacy for 24 hours and long-lasting anti-inflammatory effect3-5
Good adherence with an easy-to-use device1,6,7
Patient information
Summary of product characteristics
Footnotes
*The primary endpoint was the proportion of patients who achieved an improvement in ACT score from baseline of ≥3 or a total ACT score of ≥20, in patients in the PEA population initiated on Relvar vs continuing on usual care (ICS or ICS/LABA) at 24 weeks. The primary endpoint was met (p<0.0001). Data presented are from a subset of patients prescribed ICS/ LABA at baseline who were initiated on Relvar or continued on their ICS/LABA. Data showed a relative difference of 25% and an absolute difference of 14%.2 In this study there was no difference in serious adverse events reported between Relvar and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia.2
Abbreviations
ACT, Asthma Control Test; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; PEA, primary effectiveness analysis; PRD, proactive regular dosing.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230005 June 2023
Please update your operating system or use a different device.
